ArticleNature communications2021
An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 83 citations in OpenAlex.
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.Journal of medicinal chemistry · 2026Article
- An oral immune enhancer with excellent biocompatibility for effectively strengthening body's immunity and treating cancer.Acta pharmaceutica Sinica. B · 2026Article
- Biosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination.Journal of nanobiotechnology · 2026Article
- Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy.Biomaterials research · 2026Article
- Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.Journal of medicinal chemistry · 2025Article
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.Current pharmaceutical design · 2025Review
- Enhancing in situ cancer vaccines using delivery technologies.Nature reviews. Drug discovery · 2024Review
- Nanoparticles destabilizing the cell membranes triggered by NIR light for cancer imaging and photo-immunotherapy.Nature communications · 2024Article
- Photo-Enhanced Synergistic Induction of Ferroptosis for Anti-Cancer Immunotherapy.Advanced healthcare materials · 2023Article
- Review
- Stimuli-activatable nanomedicine meets cancer theranostics.Theranostics · 2023Review
- Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems.Macromolecules · 2022Review
- Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.Cancers · 2022Review
- Review
- Industrialization's eye view on theranostic nanomedicine.Frontiers in chemistry · 2022Review
- Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers.Frontiers in bioengineering and biotechnology · 2022Review
- Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.Journal of nanobiotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunological adjuvants are essential for successful cancer vaccination. However, traditional adjuvants have some limitations, such as lack of controllability and induction of systemic toxicity, which restrict their broad application. Here, we present a light-activable immunological adjuvant (LIA), which is composed of a hypoxia-responsive amphiphilic dendrimer nanoparticle loaded with chlorin e6. Under irradiation with near-infrared light, the LIA not only induces tumour cell lysis and tumour antigen release, but also promotes the structural transformation of 2-nitroimidazole containing dendrimer to 2-aminoimidazole containing dendrimer which can activate dendritic cells via the Toll-like receptor 7-mediated signaling pathway. The LIA efficiently inhibits both primary and abscopal tumour growth and induces strong antigen-specific immune memory effect to prevent tumour metastasis and recurrence in vivo. Furthermore, LIA localizes the immunological adjuvant effect at the tumour site. We demonstrate this light-activable immunological adjuvant offers a safe and potent platform for in situ cancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.